{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:48:13Z","timestamp":1782175693363,"version":"3.54.5"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["82422015, 82270720 and 82400904"],"award-info":[{"award-number":["82422015, 82270720 and 82400904"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYYC25003"],"award-info":[{"award-number":["ZYYC25003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49333-1","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:55:27Z","timestamp":1777301727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of novel protein markers and therapeutic targets for common urological cancers by integrating large-scale human plasma proteome with the genome"],"prefix":"10.1038","volume":"16","author":[{"given":"Xinyi","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-036X","authenticated-orcid":false,"given":"Deyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"49333_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"49333_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(13)62224-2","volume":"383","author":"P Vineis","year":"2014","unstructured":"Vineis, P. & Wild, C. P. Global cancer patterns: causes and prevention. Lancet 383, 549\u2013557 (2014).","journal-title":"Lancet"},{"key":"49333_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","volume":"6","author":"G Gakis","year":"2020","unstructured":"Gakis, G. Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives. Eur. Urol. Focus 6, 632\u2013638 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"49333_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk, M. et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur. Urol. 76, 639\u2013657 (2019).","journal-title":"Eur. Urol."},{"key":"49333_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.semcancer.2022.05.014","volume":"86","author":"C Li","year":"2022","unstructured":"Li, C., Zeng, X., Qiu, S., Gu, Y. & Zhang, Y. Nanomedicine for urologic cancers: diagnosis and management. Semin. Cancer Biol. 86, 463\u2013475 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"49333_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncy.21327","volume":"121","author":"H Dimashkieh","year":"2013","unstructured":"Dimashkieh, H. et al. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 121, 591\u2013597 (2013).","journal-title":"Cancer Cytopathol."},{"key":"49333_CR7","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.3892\/ol.2017.5926","volume":"13","author":"T Lin","year":"2017","unstructured":"Lin, T. et al. Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. Oncol. Lett. 13, 3928\u20133934 (2017).","journal-title":"Oncol. Lett."},{"key":"49333_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00345-023-04381-4","volume":"41","author":"RIH Chong","year":"2023","unstructured":"Chong, R. I. H. et al. Testicular self-examination for early detection of testicular cancer. World J. Urol. 41, 941\u2013951 (2023).","journal-title":"World J. Urol."},{"key":"49333_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s00345-022-03993-6","volume":"41","author":"P Diana","year":"2023","unstructured":"Diana, P. et al. Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group. World J. Urol. 41, 929\u2013940 (2023).","journal-title":"World J. Urol."},{"key":"49333_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00345-022-03947-y","volume":"41","author":"C W\u00fcrnschimmel","year":"2023","unstructured":"W\u00fcrnschimmel, C. et al. MRI as a screening tool for prostate cancer: Current evidence and future challenges. World J. Urol. 41, 921\u2013928 (2023).","journal-title":"World J. Urol."},{"key":"49333_CR11","doi-asserted-by":"publisher","unstructured":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.20.01035.","DOI":"10.1200\/JCO.20.01035"},{"key":"49333_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"49333_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed, G. et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell 42, 2113-2123.e4 (2024).","journal-title":"Cancer Cell"},{"key":"49333_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke, A. O. et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann. Oncol. 35, 107\u2013117 (2024).","journal-title":"Ann. Oncol."},{"key":"49333_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683\u2013694 (2021).","journal-title":"N. Engl. J. Med."},{"key":"49333_CR16","doi-asserted-by":"crossref","unstructured":"T, N. et al. Circulating proteomic signature for detection of biomarkers in bladder cancer patients. Scientific reports 10, (2020).","DOI":"10.1038\/s41598-020-67929-z"},{"key":"49333_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00280-013-2333-4","volume":"73","author":"H Cs","year":"2014","unstructured":"Cs, H. et al. Circulating proteins as potential biomarkers of sunitinib and interferon-\u03b1 efficacy in treatment-na\u00efve patients with metastatic renal cell carcinoma. Cancer Chemother. Pharmacol. 73, 151\u2013161 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"49333_CR18","doi-asserted-by":"publisher","first-page":"0891","DOI":"10.1126\/scitranslmed.aav0891","volume":"11","author":"L Puca","year":"2019","unstructured":"Puca, L. et al. Delta-like protein 31 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, 0891 (2019).","journal-title":"Sci. Transl. Med."},{"key":"49333_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612797","volume":"24","author":"G Rafikova","year":"2023","unstructured":"Rafikova, G., Gilyazova, I., Enikeeva, K., Pavlov, V. & Kzhyshkowska, J. Prostate cancer: genetics, epigenetics and the need for immunological biomarkers. Int. J. Mol. Sci. 24, 12797 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"49333_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep23594","volume":"6","author":"Y Qu","year":"2016","unstructured":"Qu, Y. et al. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Sci. Rep. 6, 23594 (2016).","journal-title":"Sci. Rep."},{"key":"49333_CR21","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1245\/s10434-009-0488-3","volume":"16","author":"R Gangwar","year":"2009","unstructured":"Gangwar, R., Mandhani, A. & Mittal, R. D. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. Ann. Surg. Oncol. 16, 2028\u20132034 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"49333_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004759","volume":"10","author":"M Fehlings","year":"2022","unstructured":"Fehlings, M. et al. Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. J. Immunother. Cancer. 10, e004759 (2022).","journal-title":"J. Immunother. Cancer."},{"key":"49333_CR23","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1158\/1078-0432.CCR-12-0955","volume":"18","author":"K Shimada","year":"2012","unstructured":"Shimada, K. et al. ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak\/Fn14\/VEGF signals. Clin. Cancer Res. 18, 5247\u20135255 (2012).","journal-title":"Clin. Cancer Res."},{"key":"49333_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1155\/2011\/108631","volume":"34","author":"V Pelekanou","year":"2011","unstructured":"Pelekanou, V. et al. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal. Cell Pathol. (Amst.) 34, 49\u201360 (2011).","journal-title":"Anal. Cell Pathol. (Amst.)"},{"key":"49333_CR25","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1172\/JCI131133","volume":"130","author":"A Alajati","year":"2020","unstructured":"Alajati, A. et al. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. J. Clin. Invest. 130, 2435\u20132450 (2020).","journal-title":"J. Clin. Invest."},{"key":"49333_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.prp.2017.02.007","volume":"213","author":"S Baspinar","year":"2017","unstructured":"Baspinar, S., Bircan, S., Ciris, M., Karahan, N. & Bozkurt, K. K. Expression of NGF, GDNF and MMP-9 in prostate carcinoma. Pathol. Res. Pract. 213, 483\u2013489 (2017).","journal-title":"Pathol. Res. Pract."},{"key":"49333_CR27","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.18632\/aging.205934","volume":"16","author":"J Xu","year":"2024","unstructured":"Xu, J., Chen, R., Yang, Y., Xu, S. & Yao, L. Genetically predicted 91 circulating inflammatory proteins in relation to risk of urological malignancies: a Mendelian randomization study. Aging (Albany NY) 16, 10366\u201310379 (2024).","journal-title":"Aging (Albany NY)"},{"key":"49333_CR28","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712\u20131721 (2021).","journal-title":"Nat. Genet."},{"key":"49333_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"49333_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"B J","year":"2019","unstructured":"J, B. & Mv, H. Meta-analysis and Mendelian randomization: a review. Res. Synth. Method. 10, 486\u2013496 (2019).","journal-title":"Res. Synth. Method."},{"key":"49333_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41467-017-02317-2","volume":"9","author":"Z Zhu","year":"2018","unstructured":"Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat. Commun. 9, 224 (2018).","journal-title":"Nat. Commun."},{"key":"49333_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12967-023-04474-z","volume":"21","author":"Y Cao","year":"2023","unstructured":"Cao, Y., Yang, Y., Hu, Q. & Wei, G. Identification of potential drug targets for rheumatoid arthritis from genetic insights: A Mendelian randomization study. J. Transl. Med. 21, 616 (2023).","journal-title":"J. Transl. Med."},{"key":"49333_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13073-023-01229-9","volume":"15","author":"J Sun","year":"2023","unstructured":"Sun, J. et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 15, 75 (2023).","journal-title":"Genome Med."},{"key":"49333_CR34","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-2145","author":"P Yao","year":"2024","unstructured":"Yao, P. et al. Proteomic analyses in diverse populations improved risk prediction and identified new drug targets for type 2 diabetes. Diabetes Care https:\/\/doi.org\/10.2337\/dc23-2145 (2024).","journal-title":"Diabetes Care"},{"key":"49333_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41588-020-0622-5","volume":"52","author":"SA Gagliano Taliun","year":"2020","unstructured":"Gagliano Taliun, S. A. et al. Exploring and visualizing large-scale genetic associations by using PheWeb. Nat. Genet. 52, 550\u2013552 (2020).","journal-title":"Nat. Genet."},{"key":"49333_CR36","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s41588-021-00954-4","volume":"53","author":"L Jiang","year":"2021","unstructured":"Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool for biobank-scale data. Nat. Genet. 53, 1616\u20131621 (2021).","journal-title":"Nat. Genet."},{"key":"49333_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508\u2013518 (2023).","journal-title":"Nature"},{"key":"49333_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).","journal-title":"Elife"},{"issue":"23","key":"49333_CR39","doi-asserted-by":"publisher","first-page":"00147","DOI":"10.1016\/j.jare.2023.05.008","volume":"S2090\u20131232","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. Insights into modifiable risk factors of erectile dysfunction, a wide-angled Mendelian Randomization study. J. Adv. Res. S2090\u20131232(23), 00147\u201300149. https:\/\/doi.org\/10.1016\/j.jare.2023.05.008 (2023).","journal-title":"J. Adv. Res."},{"key":"49333_CR40","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512\u2013525 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"49333_CR41","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucl. Acid. Res. 44, D457-462 (2016).","journal-title":"Nucl. Acid. Res."},{"key":"49333_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata, H. et al. KEGG: Kyoto encyclopedia of genes and genomes. Nucl. Acid. Res. 27, 29\u201334 (1999).","journal-title":"Nucl. Acid. Res."},{"key":"49333_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).","journal-title":"PLoS Genet."},{"key":"49333_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481\u2013487 (2016).","journal-title":"Nat. Genet."},{"key":"49333_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucl. Acid. Res. 44, e71 (2016).","journal-title":"Nucl. Acid. Res."},{"key":"49333_CR46","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2024.02.002","volume":"42","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. PDGFR\u03b1+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell 42, 682-700.e12 (2024).","journal-title":"Cancer Cell"},{"key":"49333_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat. Cell Biol. 23, 87\u201398 (2021).","journal-title":"Nat. Cell Biol."},{"key":"49333_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/path.5751","volume":"255","author":"DB Joseph","year":"2021","unstructured":"Joseph, D. B. et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J. Pathol. 255, 141\u2013154 (2021).","journal-title":"J. Pathol."},{"key":"49333_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"49333_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"49333_CR51","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour, S. L. et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucl. Acid. Res. 49, D1144\u2013D1151 (2021).","journal-title":"Nucl. Acid. Res."},{"key":"49333_CR52","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucl. Acid. Res 46, D1074\u2013D1082 (2018).","journal-title":"Nucl. Acid. Res"},{"key":"49333_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1631\/jzus.B2000711","volume":"22","author":"H Geng","year":"2021","unstructured":"Geng, H. et al. Exosomes in bladder cancer: Novel biomarkers and targets. J. Zhejiang Univ. Sci. B 22, 341\u2013347 (2021).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"49333_CR54","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.ejca.2013.05.019","volume":"49","author":"HW Kang","year":"2013","unstructured":"Kang, H. W. et al. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients. Eur. J. Cancer 49, 3010\u20133019 (2013).","journal-title":"Eur. J. Cancer"},{"key":"49333_CR55","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/15287390801988087","volume":"71","author":"K Golka","year":"2008","unstructured":"Golka, K. et al. The influence of polymorphisms of glutathione S-transferases M1 and M3 on the development of human urothelial cancer. J. Toxicol. Environ. Health A 71, 881\u2013886 (2008).","journal-title":"J. Toxicol. Environ. Health A"},{"key":"49333_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5014-1","volume":"18","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Association of glutathione S-transferase gene polymorphism with bladder cancer susceptibility. BMC Cancer 18, 1088 (2018).","journal-title":"BMC Cancer"},{"key":"49333_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrurol.2009.49","volume":"6","author":"T Simic","year":"2009","unstructured":"Simic, T., Savic-Radojevic, A., Pljesa-Ercegovac, M., Matic, M. & Mimic-Oka, J. Glutathione S-transferases in kidney and urinary bladder tumors. Nat. Rev. Urol. 6, 281\u2013289 (2009).","journal-title":"Nat. Rev. Urol."},{"key":"49333_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"49333_CR59","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam, F. et al. Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer. Clin. Cancer Res. 25, 2033\u20132041 (2019).","journal-title":"Clin. Cancer Res."},{"key":"49333_CR60","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","volume":"75","author":"TZ Tan","year":"2019","unstructured":"Tan, T. Z., Rouanne, M., Tan, K. T., Huang, R.Y.-J. & Thiery, J.-P. Molecular subtypes of urothelial bladder cancer: Results from a meta-cohort analysis of 2411 tumors. Eur. Urol. 75, 423\u2013432 (2019).","journal-title":"Eur. Urol."},{"key":"49333_CR61","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1186\/s12885-019-6244-6","volume":"19","author":"N Albarakati","year":"2019","unstructured":"Albarakati, N., Khayyat, D., Dallol, A., Al-Maghrabi, J. & Nedjadi, T. The prognostic impact of GSTM1\/GSTP1 genetic variants in bladder cancer. BMC Cancer 19, 991 (2019).","journal-title":"BMC Cancer"},{"key":"49333_CR62","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","volume":"95","author":"RE Reiter","year":"1998","unstructured":"Reiter, R. E. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 95, 1735\u20131740 (1998).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49333_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/carcin\/bgy151","volume":"40","author":"H Cui","year":"2019","unstructured":"Cui, H. et al. Variants in the PSCA gene associated with risk of cancer and nonneoplastic diseases: Systematic research synopsis, meta-analysis and epidemiological evidence. Carcinogenesis 40, 70\u201383 (2019).","journal-title":"Carcinogenesis"},{"key":"49333_CR64","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1073\/pnas.1202189109","volume":"109","author":"Y-P Fu","year":"2012","unstructured":"Fu, Y.-P. et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc. Natl. Acad. Sci. U. S. A. 109, 4974\u20134979 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49333_CR65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1471-2407-10-129","volume":"10","author":"E Marra","year":"2010","unstructured":"Marra, E. et al. Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer 10, 129 (2010).","journal-title":"BMC Cancer"},{"key":"49333_CR66","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jjco\/hyp181","volume":"40","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi, T. et al. Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn. J. Clin. Oncol. 40, 319\u2013326 (2010).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"49333_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.urolonc.2011.02.004","volume":"31","author":"Z Zhao","year":"2013","unstructured":"Zhao, Z. et al. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells. Urol. Oncol. 31, 343\u2013351 (2013).","journal-title":"Urol. Oncol."},{"key":"49333_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1586\/14737140.2014.845372","volume":"14","author":"X Yang","year":"2014","unstructured":"Yang, X. et al. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications. Expert. Rev. Anticancer. Ther. 14, 31\u201337 (2014).","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"49333_CR69","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/annonc\/mdt066","volume":"24","author":"BM Wolpin","year":"2013","unstructured":"Wolpin, B. M. et al. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann. Oncol. 24, 1792\u20131801 (2013).","journal-title":"Ann. Oncol."},{"key":"49333_CR70","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pros.22781","volume":"74","author":"C Neslund-Dudas","year":"2014","unstructured":"Neslund-Dudas, C. et al. Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer. Prostate 74, 637\u2013646 (2014).","journal-title":"Prostate"},{"key":"49333_CR71","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202103033","volume":"221","author":"X Deng","year":"2022","unstructured":"Deng, X. et al. CHMP2B regulates TDP-43 phosphorylation and cytotoxicity independent of autophagy via CK1. J. Cell Biol. 221, e202103033 (2022).","journal-title":"J. Cell Biol."},{"key":"49333_CR72","doi-asserted-by":"publisher","first-page":"28494","DOI":"10.18632\/oncotarget.15312","volume":"8","author":"T Peng","year":"2017","unstructured":"Peng, T., Zhang, L., Zhu, L. & Mi, Y.-Y. MSMB gene rs10993994 polymorphism increases the risk of prostate cancer. Oncotarget 8, 28494\u201328501 (2017).","journal-title":"Oncotarget"},{"key":"49333_CR73","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/hmg\/ddab347","volume":"31","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation. Hum. Mol. Genet. 31, 1610\u20131621 (2022).","journal-title":"Hum. Mol. Genet."},{"key":"49333_CR74","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x2025e14445","volume":"58","author":"J Xie","year":"2025","unstructured":"Xie, J., Chen, Q., Li, L. & Liu, J. Overexpression of SERPINA3 inhibits castration-resistant prostate cancer progression by enhancing M1 macrophage recruitment via CXCL2 upregulation. Braz. J. Med. Biol. Res. 58, e14445 (2025).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"49333_CR75","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/fon-2021-1288","volume":"18","author":"MJ Burke","year":"2022","unstructured":"Burke, M. J. & Zalewska-Szewczyk, B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: Immunology and clinical consequences. Futur. Oncol. 18, 1285\u20131299 (2022).","journal-title":"Futur. Oncol."},{"key":"49333_CR76","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","volume":"174","author":"P Gao","year":"2018","unstructured":"Gao, P. et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. Cell 174, 576-589.e18 (2018).","journal-title":"Cell"},{"key":"49333_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-025-05276-1","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. TOR1 AIP1 interacts with p53 to enhance cell cycle dysregulation in prostate cancer progression. Mol. Cell. Biochem. https:\/\/doi.org\/10.1007\/s11010-025-05276-1 (2025).","journal-title":"Mol. Cell. Biochem."},{"key":"49333_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-018-0789-0","volume":"37","author":"J Chen","year":"2018","unstructured":"Chen, J. et al. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer. J. Exp. Clin. Cancer Res. 37, 127 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"49333_CR79","doi-asserted-by":"publisher","first-page":"54616","DOI":"10.18632\/oncotarget.10520","volume":"7","author":"H-J Jin","year":"2016","unstructured":"Jin, H.-J., Jung, S., DebRoy, A. R. & Davuluri, R. V. Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Oncotarget 7, 54616\u201354626 (2016).","journal-title":"Oncotarget"},{"key":"49333_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.gene.2012.04.011","volume":"501","author":"A Crawford","year":"2012","unstructured":"Crawford, A. et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 501, 89\u2013103 (2012).","journal-title":"Gene"},{"key":"49333_CR81","doi-asserted-by":"publisher","first-page":"825","DOI":"10.18632\/aging.102658","volume":"12","author":"L-F Zhang","year":"2020","unstructured":"Zhang, L.-F. et al. Association between SOD2 V16A variant and urological cancer risk. Aging (Albany NY) 12, 825\u2013843 (2020).","journal-title":"Aging (Albany NY)"},{"key":"49333_CR82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/14728222.2016.1091883","volume":"20","author":"G Cozza","year":"2016","unstructured":"Cozza, G. & Pinna, L. A. Casein kinases as potential therapeutic targets. Expert Opin. Ther. Targets. 20, 319\u2013340 (2016).","journal-title":"Expert Opin. Ther. Targets."},{"key":"49333_CR83","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/cancers11121983","volume":"11","author":"C Pitolli","year":"2019","unstructured":"Pitolli, C. et al. p53-Mediated Tumor Suppression: DNA-Damage Response and Alternative Mechanisms. Cancers (Basel) 11, 1983 (2019).","journal-title":"Cancers (Basel)"},{"key":"49333_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004102","volume":"10","author":"DJ Hazelett","year":"2014","unstructured":"Hazelett, D. J. et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 10, e1004102 (2014).","journal-title":"PLoS Genet."},{"key":"49333_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/humu.22176","volume":"34","author":"LM FitzGerald","year":"2013","unstructured":"FitzGerald, L. M. et al. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum. Mutat. 34, 149\u2013156 (2013).","journal-title":"Hum. Mutat."},{"key":"49333_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pros.23466","volume":"78","author":"SH Bergstr\u00f6m","year":"2018","unstructured":"Bergstr\u00f6m, S. H., J\u00e4remo, H., Nilsson, M., Adamo, H. H. & Bergh, A. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. Prostate 78, 257\u2013265 (2018).","journal-title":"Prostate"},{"key":"49333_CR87","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/pros.21149","volume":"70","author":"B Xu","year":"2010","unstructured":"Xu, B. et al. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 70, 1146\u20131152 (2010).","journal-title":"Prostate"},{"key":"49333_CR88","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171329","volume":"38","author":"X Zhu","year":"2018","unstructured":"Zhu, X. et al. AGER promotes proliferation and migration in cervical cancer. Biosci. Rep. 38, BSR20171329 (2018).","journal-title":"Biosci. Rep."},{"key":"49333_CR89","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ijc.30512","volume":"140","author":"C Bodelon","year":"2017","unstructured":"Bodelon, C. et al. Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. Int. J. Cancer 140, 825\u2013832 (2017).","journal-title":"Int. J. Cancer"},{"key":"49333_CR90","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1186\/s12967-023-04525-5","volume":"21","author":"F Ren","year":"2023","unstructured":"Ren, F., Jin, Q., Liu, T., Ren, X. & Zhan, Y. Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers. J. Transl. Med. 21, 646 (2023).","journal-title":"J. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49333-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49333-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49333-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:05:33Z","timestamp":1782173133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49333-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49333"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49333-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19438"}}